Cryoport Inc
NASDAQ:CYRX
Cryoport Inc
CryoPort, Inc. engages in the provision of logistics solutions to the life science industry. The company is headquartered in Brentwood, Tennessee and currently employs 791 full-time employees. The company went IPO on 2015-07-24. The firm provides supply chain technologies and services through its brands, such as Cryoport Systems, CryoStork, MVE Biological Solutions, CRYOPDP, and CRYOGENE. The firm's products include Cryoport Express Shippers, Cryoport ELITE Shippers, Cryoport Cryosphere, Cryoport Consulting Services, Cryoport Bioservices, CRYOGENE, CRYOPDP Temperature Controlled Logistics, CRYOPDP Direct to Patient Solutions, CRYOPDP Control Tower Solution, MVE Biological Solutions Fusion Cryogenic Freezers and MVE Biological Solutions Vario Cryogenic Freezer. The company operates primarily in Americas; Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC). Its subsidiaries include Cryoport Systems, LLC, Cryogene, Inc., MVE Biological Solutions, US LLC, Cryoport Netherlands B.V., and Cell&Co BioServices.
CryoPort, Inc. engages in the provision of logistics solutions to the life science industry. The company is headquartered in Brentwood, Tennessee and currently employs 791 full-time employees. The company went IPO on 2015-07-24. The firm provides supply chain technologies and services through its brands, such as Cryoport Systems, CryoStork, MVE Biological Solutions, CRYOPDP, and CRYOGENE. The firm's products include Cryoport Express Shippers, Cryoport ELITE Shippers, Cryoport Cryosphere, Cryoport Consulting Services, Cryoport Bioservices, CRYOGENE, CRYOPDP Temperature Controlled Logistics, CRYOPDP Direct to Patient Solutions, CRYOPDP Control Tower Solution, MVE Biological Solutions Fusion Cryogenic Freezers and MVE Biological Solutions Vario Cryogenic Freezer. The company operates primarily in Americas; Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC). Its subsidiaries include Cryoport Systems, LLC, Cryogene, Inc., MVE Biological Solutions, US LLC, Cryoport Netherlands B.V., and Cell&Co BioServices.
Strong Double-Digit Growth: Both Life Sciences Services and Product segments posted double-digit revenue gains, with Services up 16% year-over-year and Product up 15%.
Commercial Therapy Support: Revenue from supporting commercial cell and gene therapies rose 36% year-over-year to $8.3 million.
Full-Year Guidance Raised: 2025 revenue guidance increased to $170–$174 million, reflecting 8–11% growth over the prior year.
Close to Profitability: Adjusted EBITDA loss narrowed to $600,000 in Q3; management expects to reach positive EBITDA as early as year-end or in early 2026.
New Facilities & Investments: Cryoport opened a new global supply chain center in Paris and is building another in California, aiming to drive future operating leverage and support growth.
Resilient Demand & Pipeline: Despite pharma exits and macro headwinds, clinical trial activity remains robust with 745 trials supported and 83 in Phase III.
